From: Biomarker testing in MCI patients—deciding who to test
Total n = 402 | Non-progressors n = 213 | Progressors n = 189 | |
---|---|---|---|
Age | 66 ± 8 | 65 ± 8 | 67 ± 8 |
Sex, No. F (%) | 164 (41%) | 76 (36%) | 88 (47%) |
MMSE | 27 ± 2 | 27 ± 2 | 26 ± 3 |
Follow-up | 3 ± 2 | 3 ± 2 | 3 ± 2 |
MRI | |||
HCV (cm3, sum) | 6.8 ± 1 | 7.1 ± 1 | 6.5 ± 1 |
CSF | |||
Abeta (1-42) pg/ml | 778 (652–1083) | 976 (732–1191) | 686 (596–783) |
t-tau pg/ml | 397 (265–626) | 291 (207–422) | 566 (379–794) |
pTau pg/ml | 62 (44–85) | 51 (36–69) | 76 (59–100) |